Innate Immune, Inc., a private biotechnology company, today announced that it has granted an exclusive license to patents for the development of its antibodies for the treatment of asthma and systemic lupus erythematosis (SLE) to Cephalon Australia Pty Ltd.

In the agreement, Cephalon Australia will use their proprietary technology to humanize the antibodies and conduct all development and clinical work related to the product candidate(s).

During the early development, Innate Immune had demonstrated that the blocking of the activation of natural killer T (NKT) cells using the antibody was effective for treating asthma and SLE in preclinical animal models.

Andrew Perlman, M.D., Ph.D., founder and CEO of Innate Immune said, Based on our deep understanding of the pivotal role NKY cells play in human health and disease, we have built a strong portfolio of therapeutic leads against multiple disease indications.

We look forward to Cephalon Australia's further development of this exciting product candidate which has the potential to address important medical needs.

Innate Immune, Inc. is a privately held biotechnology company which is focused on the discovery and development of drugs that regulate the activity of natural killer T (NKT) cells for the purpose of treating immune disorders.